Study: Has prescription monitoring curbed the opioid epidemic?
Mandated PDMP use in US states reduced opioid prescriptions by 6.1% but led to a 50.1% increase in heroin-related deaths, according to researchers from the University of Texas at Dallas.
Pharmacological Inhibitors
Articles tagged with Pharmacological Inhibitors
Drug that lowers blood sugar also reduces blood vessel dysfunction caused by aging
Researchers discovered Empa, an FDA-approved diabetes medication, improved blood vessel function and reduced arterial stiffness in aged male mice. The study suggests SGLT2 inhibition may be a therapeutic tool to delay or reverse vascular aging in humans.
Novel preclinical drug could have potential to combat depression, brain injury and cognitive disorders
A novel preclinical drug has been developed to inhibit the kinase enzyme Cdk5, which is implicated in neuropsychiatric and neurodegenerative conditions. The drug, 25-106, is brain-permeable and shows promise in altering neurobehavior in mice with anxiety-like behavior.
Biomed Valley Discoveries announces poster presentations on Ulixertinib (BVD-523) at the AACR Annual Meeting 2022
Biomed Valley Discoveries will present four posters on ulixertinib (BVD-523), a first-in-class ERK1/2 inhibitor, at the AACR Annual Meeting 2022. The presentations focus on ulixertinib's potential in combating acquired resistance to the drug and its efficacy in combination with other therapies.
A potential new approach for the treatment of schizophrenia
Vanderbilt researchers discover how a protein may treat schizophrenia, including reversing working memory deficits. Enhancing the activity of mGlu1 selectively increases the activity of specific inhibitory interneurons, restoring their ability to inhibit neuronal circuits.
Ivy Brain Tumor Center announces results from Phase 0/1 clinical trial of ribociclib plus everolimus in recurrent high-grade glioma
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
Research reveals that inhibiting Mcl-1 protein can induce apoptosis in estrogen receptor-positive breast cancer cells, suggesting a potential therapeutic strategy for this type of cancer. The study also found that combining Mcl-1 inhibition with ABT-263 increased cell death in ER+ breast cancer cells.
Erectile dysfunction drugs may help treat many other conditions
PDE5 inhibitors have been approved to treat lower urinary tract symptoms and pulmonary arterial hypertension, with potential benefits in diabetes and cancer treatment due to their blood vessel dilation effects
SHIP1 inhibitor reduces obesity and metabolic dysfunction in mice
A new study led by William Kerr of SUNY Upstate Medical University found that SHIP1 inhibition improved metabolic phenotypes in mice fed a high-fat diet. The results showed that SHIP1 inhibition prevented excess weight gain, improved blood sugar control, and reduced inflammation in adipose tissue.
Slow-binding inhibition of cholinesterases: Pharmacological and toxicological relevance
Researchers discovered slow-binding inhibitors (SBIs) with high selectivity, long target-residence times, and minimal side effects for treating Alzheimer's disease, myasthenia, and neuroprotection. SBIs also have toxicological importance, playing a role in mechanisms of resistance against irreversible agents.
Researchers identify and block protein that interferes with appetite-suppressing hormone
University of Texas Medical Branch researchers have identified a protein called Epac1 that blocks leptin's activity in the brain. Blocking this protein can increase leptin sensitivity and lead to lower body weight, body fat percentage, blood plasma leptin levels, and improved glucose tolerance.
Fragile X syndrome can be reversed in adult mouse brain
A recent study reverses many Fragile X syndrome symptoms in adult mice using a new compound CTEP. The study found that pharmacologic inhibition of mGlu5 receptor can correct FXS symptoms, including learning and memory deficits and auditory hypersensitivity.
University of Pennsylvania study shows cardioprotective benefits of aspirin inhibited when preceded by ibuprofen
A University of Pennsylvania study suggests that taking ibuprofen before aspirin can inhibit the cardioprotective benefits gained from a daily aspirin regimen. The study found no competitive interaction between aspirin and Tylenol or Vioxx when taken separately.
Scientists cause human cancer cell death by inhibiting telomerase
Researchers at UT Southwestern Medical Center designed and tested synthetic inhibitors against telomerase, a key enzyme in cancer cell immortality. These inhibitors successfully caused progressive telomere shortening and cell death in human breast and prostate cancer cells.
Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory
Researchers at Thomas Jefferson University and Oxford University have found a promising drug against the hepatitis C virus (HCV), called N-nonyl-DNJ, which inhibits the activity of an important cellular enzyme, glucosidase. This drug may sidestep resistant viruses, a major problem with current treatments.
How Super Are The "Super Aspirins"? -- New COX-2 Inhibitors May Elevate Cardiovascular Risk
Researchers found that COX-2 inhibitors suppress prostacyclin, a hormone-like substance produced in blood vessels, which can lead to increased thrombosis risk. This discovery raises concerns about the potential cardiovascular risks of these new pain relievers.
The Heart-Healthy Cup Runneth Over -- With Grape Juice
A study by Jane E. Freedman found that purple grape juice inhibits platelet aggregation, reducing blood clotting risk and improving cardiovascular health. The flavonoid quercetin was also shown to have antioxidant properties, preventing the inactivation of nitric oxide.
Inhibitor Shows Potential To Protect Infant Brain
Researchers at Washington University School of Medicine have shown that a compound called BAF protects newborn rats from brain damage. The findings suggest that administering BAF after the damaging procedure is just as effective as giving it ahead of time, and that it also protects when injected systemically.
Jefferson Scientists Devise Way To Treat Animals Chronically Infected With Hepatitis B
Researchers at Jefferson Medical College have found a way to inhibit the hepatitis B virus by blocking its envelope creation, resulting in a dramatic drop in viral levels. The discovery may provide new leads for treating chronic HBV and HCV infections in humans.
Rapid Progress Reported On New Class Of Anti-Cancer Drugs
Researchers have made rapid progress on a new class of anti-cancer drugs that target the Ras protein activation pathway, which causes up to 90% of pancreatic cancers. Laboratory studies have shown effective inhibition of cancer cells using FTase inhibitors.